20,000 Shares in Progyny, Inc. (NASDAQ:PGNY) Acquired by Quinn Opportunity Partners LLC

Quinn Opportunity Partners LLC purchased a new stake in shares of Progyny, Inc. (NASDAQ:PGNY) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 20,000 shares of the company’s stock, valued at approximately $345,000.

Several other hedge funds also recently modified their holdings of PGNY. GAMMA Investing LLC grew its holdings in Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after acquiring an additional 1,246 shares during the period. Signaturefd LLC boosted its position in shares of Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after purchasing an additional 1,355 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock worth $51,000 after purchasing an additional 1,526 shares during the last quarter. KBC Group NV grew its stake in shares of Progyny by 84.6% in the 4th quarter. KBC Group NV now owns 4,669 shares of the company’s stock worth $81,000 after purchasing an additional 2,140 shares during the last quarter. Finally, F M Investments LLC raised its holdings in shares of Progyny by 13.0% in the 4th quarter. F M Investments LLC now owns 20,420 shares of the company’s stock worth $352,000 after purchasing an additional 2,342 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Stock Performance

Shares of PGNY opened at $22.34 on Friday. The company has a market capitalization of $1.91 billion, a PE ratio of 38.52, a PEG ratio of 2.39 and a beta of 1.33. The company’s 50 day moving average price is $22.01 and its 200 day moving average price is $18.68. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $34.92.

Wall Street Analysts Forecast Growth

PGNY has been the topic of several recent research reports. Canaccord Genuity Group lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, February 28th. Bank of America lifted their target price on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. upped their target price on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Finally, BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a research note on Monday, March 31st. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $23.64.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.